American Cyanamid Cyglas 615

Product Description

Cyglas 615 was an industrial phenolic compound manufactured by American Cyanamid Company, a major American chemical and manufacturing corporation with operations spanning pharmaceuticals, agricultural chemicals, and specialty industrial materials. American Cyanamid produced a broad line of Cyglas-branded resins and compounds intended for industrial applications requiring high heat resistance, electrical insulation, and structural durability under demanding conditions.

Phenolic compounds in the Cyglas product line were engineered for use in environments where standard materials would degrade under thermal or chemical stress. These products were commonly used in industrial fabrication, molding applications, and manufacturing settings where heat resistance and mechanical strength were essential performance requirements. The Cyglas designation covered a range of formulations, with Cyglas 615 representing one specific compound within that product family.

American Cyanamid operated as one of the larger diversified chemical companies in the United States during the mid-twentieth century, supplying specialty materials to manufacturing industries throughout the country. The company’s industrial chemical divisions produced materials that reached workers across a wide variety of factory and production settings.

The precise production timeline for Cyglas 615 has not been independently confirmed in all available public records. Based on American Cyanamid’s broader industrial activity, products of this type were generally produced and distributed during the decades when asbestos use in industrial compounds was prevalent and largely unregulated — a period spanning roughly from the mid-twentieth century through the 1970s and into the early 1980s, before regulatory action by OSHA and the EPA began to curtail asbestos use in manufacturing materials.

Asbestos Content

Phenolic compounds and resins of this era were among the many categories of industrial materials that incorporated asbestos fibers as a functional additive. In phenolic molding compounds and related products, asbestos served as a reinforcing filler and thermal stabilizer, improving the material’s resistance to heat distortion, increasing mechanical strength, and enhancing dimensional stability during curing and end use.

Asbestos fibers — most commonly chrysotile, though amphibole varieties were also used in industrial compounds — were blended directly into resin matrices during the manufacturing process. This integration meant that the finished compound contained asbestos throughout its structure, not merely as a surface coating or external additive. As a result, any mechanical work performed on the cured material — cutting, grinding, drilling, sanding, or machining — had the potential to release respirable asbestos fibers into the surrounding work environment.

The specific asbestos content, fiber type, and concentration present in Cyglas 615 as documented in litigation records has been the subject of legal proceedings. Plaintiffs alleged that American Cyanamid incorporated asbestos into Cyglas 615 and that the company was aware, or should have been aware, of the health hazards associated with asbestos fiber inhalation during normal foreseeable use of the product.

Regulatory documentation from AHERA and OSHA’s asbestos standards confirms that asbestos-containing phenolic compounds represent a category of material capable of releasing hazardous fiber concentrations when disturbed. OSHA’s permissible exposure limits for asbestos, established and subsequently lowered over successive decades, reflect the recognized danger of occupational asbestos exposure in exactly the types of industrial settings where products like Cyglas 615 were used.

How Workers Were Exposed

Industrial workers represent the primary population with documented exposure to Cyglas 615. Litigation records identify general industrial workers — those employed in manufacturing, fabrication, and processing environments — as the individuals most likely to have encountered this product during ordinary work activities.

Exposure pathways in industrial settings involving phenolic asbestos compounds typically included:

• Handling raw compound materials during mixing, loading, or preparation stages, when loose fiber-containing materials could become airborne
• Machining and finishing operations performed on cured phenolic parts, including drilling, cutting, grinding, and sanding, which generated fine dust containing asbestos fibers
• Demolding and trimming of molded components, during which flash and excess material was removed by mechanical or manual abrasion
• Housekeeping and cleanup activities in facilities where phenolic compounds were processed, where accumulated dust on surfaces and equipment could be resuspended
• Proximity exposure for workers stationed near operations involving these materials, even when not directly handling the compound

Asbestos fibers released during these activities are microscopic and remain suspended in air for extended periods. Workers in facilities without adequate ventilation or respiratory protection would have inhaled these fibers during the course of routine tasks, often without any visible indication that exposure was occurring.

Plaintiffs alleged that American Cyanamid failed to provide adequate warnings about the asbestos content of Cyglas 615 and the associated health risks, and that this failure deprived workers of the opportunity to take protective measures. Litigation records document claims that workers were not informed that the product contained asbestos and were not provided with guidance on safe handling procedures, protective equipment, or the need for medical monitoring.

The diseases associated with occupational asbestos exposure — including mesothelioma, asbestosis, lung cancer, and other asbestos-related conditions — typically have latency periods of 20 to 50 years between initial exposure and clinical diagnosis. This means workers exposed to Cyglas 615 during peak decades of industrial production may only now be receiving diagnoses linked to that historical exposure.

Documented Trust Fund / Legal Options

American Cyanamid Cyglas 615 falls within Tier 2 of asbestos litigation documentation. There is no confirmed dedicated asbestos bankruptcy trust fund established specifically by American Cyanamid for Cyglas 615 claims at the time of this writing. Legal claims related to this product have proceeded through the civil tort litigation system rather than through a structured trust fund claims process.

Litigation records document lawsuits filed by industrial workers and, in cases involving fatal asbestos disease, by surviving family members, alleging personal injury and wrongful death caused by exposure to asbestos-containing products including Cyglas 615. Plaintiffs alleged negligence, failure to warn, and product liability theories against American Cyanamid in connection with this and related products.

Individuals who believe they were exposed to American Cyanamid Cyglas 615 and have subsequently been diagnosed with an asbestos-related disease should consult with a qualified asbestos attorney to evaluate available legal options. An experienced attorney can:

• Review employment and exposure history to document contact with Cyglas 615
• Identify all potentially responsible parties, which may include manufacturers, distributors, and premises owners
• Evaluate whether any related trust fund claims may apply based on co-exposures to other asbestos-containing products
• Assess statutes of limitations, which vary by state and typically begin running from the date of diagnosis rather than the date of exposure

Because asbestos litigation is governed by state-specific procedural rules and limitation periods, prompt consultation is important for preserving legal rights. Workers diagnosed with mesothelioma, lung cancer, asbestosis, or pleural disease with a history of industrial work should specifically raise the possibility of phenolic compound exposure when speaking with legal counsel.

This article is provided for informational and reference purposes. It is based on litigation records, regulatory documentation, and publicly available product information. It does not constitute legal advice.